{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:45:56Z","timestamp":1790815556666,"version":"4.1.0"},"reference-count":61,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Five core domains have been endorsed by Outcome Measures in Rheumatology (OMERACT) for acute gout: pain, joint swelling, joint tenderness, patient global assessment, and activity limitation. We evaluated instruments for these domains according to the OMERACT filter: truth, feasibility, and discrimination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A systematic search strategy for instruments used to measure the acute gout core domains was formulated. For each method, articles were assessed by 2 reviewers to summarize information according to the specific components of the OMERACT filter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Seventy-seven articles and abstracts met the inclusion criteria. Pain was most frequently reported (76 studies, 20 instruments). The pain instruments used most often were 100 mm visual analog scale (VAS) and 5-point Likert scale. Both methods have high feasibility, face and content validity, and within- and between-group discrimination. Four-point Likert scales assessing index joint swelling and tenderness have been used in numerous acute gout studies; these instruments are feasible, with high face and content validity, and show within- and between-group discrimination. Five-point Patient Global Assessment of Response to Treatment (PGART) scales are feasible and valid, and show within- and between-group discrimination. Measures of activity limitations were infrequently reported, and insufficient data were available to make definite assessments of the instruments for this domain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Many different instruments have been used to assess the acute gout core domains. Pain VAS and 5-point Likert scales, 4-point Likert scales of index joint swelling and tenderness and 5-point PGART instruments meet the criteria for the OMERACT filter.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.131244","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T01:14:20Z","timestamp":1387156460000},"page":"558-568","source":"Crossref","is-referenced-by-count":31,"title":["Outcome Measures in Acute Gout: A Systematic Literature Review"],"prefix":"10.3899","volume":"41","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy S.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja P.","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M.","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,12,15]]},"reference":[{"key":"2018112909325339000_41.3.558.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"2018112909325339000_41.3.558.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110272"},{"key":"2018112909325339000_41.3.558.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090371"},{"key":"2018112909325339000_41.3.558.4","first-page":"2452","article-title":"Outcome measures for acute and chronic gout","volume":"32","author":"Schumacher","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090370"},{"key":"2018112909325339000_41.3.558.6","first-page":"1381","article-title":"Outcome evaluations in gout","volume":"34","author":"Schumacher","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110271"},{"key":"2018112909325339000_41.3.558.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110273"},{"key":"2018112909325339000_41.3.558.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079970"},{"key":"2018112909325339000_41.3.558.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110274"},{"key":"2018112909325339000_41.3.558.11","first-page":"198","article-title":"The OMERACT filter for Outcome Measures in Rheumatology","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.12","first-page":"S400","article-title":"Pharmacological treatment of acute gout: a systematic review","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2018112909325339000_41.3.558.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.27600"},{"key":"2018112909325339000_41.3.558.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.30120"},{"key":"2018112909325339000_41.3.558.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1987.tb01232.x"},{"key":"2018112909325339000_41.3.558.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03132.x"},{"key":"2018112909325339000_41.3.558.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1488"},{"key":"2018112909325339000_41.3.558.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar3297"},{"key":"2018112909325339000_41.3.558.19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20015"},{"key":"2018112909325339000_41.3.558.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20007"},{"key":"2018112909325339000_41.3.558.21","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800504"},{"key":"2018112909325339000_41.3.558.22","first-page":"26","article-title":"Evaluation of tenoxicam in rheumatology\u2014clinical trial results in Argentina and Brazil","volume":"9","author":"Barclay","year":"1987","journal-title":"Eur J Rheumatol Inflamm"},{"key":"2018112909325339000_41.3.558.23","first-page":"111","article-title":"Piroxicam in treatment of acute gout high dose versus low dose","volume":"68","author":"Tumrasvin","year":"1985","journal-title":"J Med Assoc Thai"},{"key":"2018112909325339000_41.3.558.24","doi-asserted-by":"publisher","DOI":"10.1185\/03007999109111513"},{"key":"2018112909325339000_41.3.558.25","first-page":"344","article-title":"A double-blind comparison of Etodolac (Lodine\u00ae) and high doses of naproxen in the treatment of acute gout","volume":"7","author":"Lederman","year":"1990","journal-title":"Adv Ther"},{"key":"2018112909325339000_41.3.558.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20670"},{"issue":"Suppl II","key":"2018112909325339000_41.3.558.27","first-page":"234","article-title":"Validation of a patient-reported assessment of pain in acute gouty arthritis","volume":"66","author":"Schlesinger","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2018112909325339000_41.3.558.28","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X95000316"},{"key":"2018112909325339000_41.3.558.29","first-page":"400","article-title":"Looking for important change\/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal clinically important Difference","volume":"28","author":"Beaton","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2006.11.014"},{"key":"2018112909325339000_41.3.558.31","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60799-0"},{"issue":"Suppl 3","key":"2018112909325339000_41.3.558.33","first-page":"181","article-title":"Long-term safety and efficacy of canakinumab (ACZ885) in the prevention of flares in gouty arthritis patients","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"2018112909325339000_41.3.558.34","first-page":"121","article-title":"Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: Results of the b-relieved ii study (response in acute flare and in prevention of episodes of re-flare in gout)","volume":"69","author":"Schlesinger","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2018112909325339000_41.3.558.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127621"},{"key":"2018112909325339000_41.3.558.36","first-page":"S398","article-title":"Effect of IL-1 inhibition with canakinumab compared to triamcinolone acetonide on pain intensity and new flares in gouty arthritis patients with chronic kidney disease stage 2\u20135","volume":"63","author":"Sunkureddi","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2018112909325339000_41.3.558.37","first-page":"65","article-title":"Diclofenac Duo 0.075 for treatment of patients with coxarthrosis, gonarthrosis and gout","volume":"39","author":"Bochev","year":"2003","journal-title":"Ortopediya Travmatologiya"},{"key":"2018112909325339000_41.3.558.38","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(94)90061-2"},{"key":"2018112909325339000_41.3.558.39","doi-asserted-by":"publisher","DOI":"10.1007\/BF02836525"},{"key":"2018112909325339000_41.3.558.40","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fernandez","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90035-5"},{"key":"2018112909325339000_41.3.558.42","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X210750"},{"key":"2018112909325339000_41.3.558.43","doi-asserted-by":"crossref","unstructured":"Ruotsi A Vainio U . Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol Suppl 1978:15\u20137.","DOI":"10.3109\/03009747809095668"},{"key":"2018112909325339000_41.3.558.44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem090"},{"key":"2018112909325339000_41.3.558.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.25034"},{"key":"2018112909325339000_41.3.558.46","doi-asserted-by":"publisher","DOI":"10.1177\/030006058201000603"},{"key":"2018112909325339000_41.3.558.47","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200729"},{"key":"2018112909325339000_41.3.558.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(86)80013-0"},{"key":"2018112909325339000_41.3.558.49","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"2018112909325339000_41.3.558.50","first-page":"275","article-title":"A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout","volume":"10","author":"Douglas","year":"1970","journal-title":"Ann Phys Med"},{"key":"2018112909325339000_41.3.558.51","first-page":"641","article-title":"Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study","volume":"33","author":"Eberl","year":"1983","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 1","key":"2018112909325339000_41.3.558.52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00003495-198800351-00016","article-title":"Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect","volume":"35","author":"Katona","year":"1988","journal-title":"Drugs"},{"key":"2018112909325339000_41.3.558.53","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-007-9001-7"},{"key":"2018112909325339000_41.3.558.54","first-page":"126","article-title":"Use of piroxicam in the treatment of acute gout","volume":"6","author":"Cobra","year":"1983","journal-title":"Eur J Rheumatol Inflamm"},{"key":"2018112909325339000_41.3.558.55","doi-asserted-by":"publisher","DOI":"10.1177\/030006057900700605"},{"key":"2018112909325339000_41.3.558.56","first-page":"365","article-title":"Efficacy, tolerance and safety of piroxicam in the treatment of acute gout","volume":"1","author":"Tausch","year":"1978","journal-title":"Eur J Rheumatol Inflamm"},{"key":"2018112909325339000_41.3.558.57","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1975.tb01465.x"},{"key":"2018112909325339000_41.3.558.58","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90131-2"},{"key":"2018112909325339000_41.3.558.59","first-page":"133","article-title":"Use of tenoxicam in patients with acute gouty arthritis","volume":"9","author":"Valdes","year":"1987","journal-title":"Eur J Rheumatol Inflamm"},{"key":"2018112909325339000_41.3.558.60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1742-1241.1985.tb07791.x","article-title":"Clinical experience with isoxicam in patients with acute gout","volume":"39","author":"Fletcher","year":"1985","journal-title":"Br J Clin Pract"},{"key":"2018112909325339000_41.3.558.61","first-page":"327","article-title":"Fentiazac in acute gouty arthritis","volume":"7","author":"Molina","year":"1985","journal-title":"Clin Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.131244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T01:12:40Z","timestamp":1688865160000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.131244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.3899\/jrheum.131244"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.131244","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}